FDA Reaffirms Bioequivalence Of Wellbutrin Generic
Despite reports of 85 patients experiencing "undesirable effects" after switching from GlaxoSmithKline's antidepressant Wellbutrin XL to a generic version marketed by Teva Pharmaceuticals Industries Ltd., the U.S. Food and Drug Administration...To view the full article, register now.
Already a subscriber? Click here to view full article